Table 5.
Prevalence of Nonpolymorphic and Polymorphic HIV-2 Integrase Mutations in INSTI-Naive and INSTI-Treated Persons Significantly Associated With INSTI Therapy
| Mutation | INSTI Naive, No. (%) (n = 236)a | INSTI Treated, No. (%) (n = 60)a | Fold | Fisher Exact Test Pb |
|---|---|---|---|---|
| Nonpolymorphic | ||||
| Q91R | 1 (0.42) | 8 (13.33) | 31.5 | .0005 |
| E92A | 0 (0) | 5 (8.33) | >>> | .01 |
| E92Q | 0 (0) | 12 (20.00) | >>> | <.000001 |
| T97A | 0 (0) | 19 (31.67) | >>> | <.000001 |
| G140S | 0 (0) | 7 (11.67) | >>> | .0004 |
| Y143G | 0 (0) | 4 (6.67) | >>> | .05 |
| Q148R | 0 (0) | 7 (11.67) | >>> | .0004 |
| A153G | 1 (0.42) | 10 (16.67) | 39.3 | .00003 |
| N155H | 1 (0.42) | 17 (28.33) | 66.9 | <.000001 |
| H156R | 2 (0.85) | 10 (16.67) | 19.7 | .0001 |
| R231 insertion | 0 (0) | 7 (12.28) | >>> | .0003 |
| Polymorphic | ||||
| I84V | 15 (6.36) | 19 (31.67) | 5.0 | .00004 |
| A119T | 4 (1.69) | 8 (13.33) | 7.9 | .02 |
| V141I | 3 (1.27) | 8 (13.33) | 10.5 | .008 |
Abbreviation: INSTI, integrase strand transfer inhibitor.
an = total number of persons from whom sequences were obtained. However, sequences encompassing position 231 were available from 57 (not 60) INSTI-treated persons.
bAdjustment for multiple hypothesis testing for all mutations occurring in ≥3 times in INSTI-experienced persons and ≥2 times more commonly in INSTI-experienced compared with INSTI-naive persons was performed using the Holm method.